News and Announcements
OncoSil (ASX: OSL) Accelerates Operational Progress with 10 Major Cancer Treatment Centres & Reports $8.0m Cash Balance
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Ltd (ASX:OSL), a medical device company which focuses on localised treatments for patients with pancreatic and liver cancer, has released its Appendix 4C – Quarterly Cashflow report for the quarter ended 30 June 2017.
KEY TAKEAWAYS:
- Accelerated operational progress, with 10 major cancer treatment centres now activated
- 13 patients now enrolled into current study (up from 1 patient at the end of FY3Q 17)
- 4 patients in study group implanted with OncoSil™ device on 21 July
- 1 Compassionate access patient implanted with OncoSil™ device on 21 July
- Cash balance as at 30 June of $8.0m, with cash outflow from operations for the quarter of $2.4m
OncoSil Chief Executive Officer, Daniel Kenny commented:
“Our team’s primary focus during the past quarter has been to continue driving patient recruitment to our activated sites which are part of our global study programme – with additional sites now on board, including leading sites in both the UK and US, we look forward to reaching our goal of 20 patients over the coming weeks, and providing the required supplemental data to BSI for CE Mark approval.
While I am encouraged by our current rate of recruitment and the growing list of globally prestigious cancer centres involved in our clinical programme, recruitment for this study is challenging.
The Company will need to accelerate operational performance in the coming weeks if it is to secure CE Mark in 2017. However, given the significant advances in 2017, and particularly in this past quarter, Oncosil’s Board is confident that we are proceeding in the right manner and should near full patient recruitment in the coming weeks.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
